PRFX News & Events

PRF Technologies announced expanded results from its previously reported preclinical study directly comparing its lead product candidate, PRF-110, to Zynrelef, an approved extended-release product used as a benchmark in the study. The expanded results characterize the pharmacokinetic and tissue-distribution properties of PRF-110 alongside the analgesic efficacy data previously announced. PRF-110 is a proprietary, oil-based, viscous, clear extended-release formulation of ropivacaine designed to be deposited directly into the surgical wound bed prior to closure. The product candidate is being developed to provide prolonged local analgesia following surgery through a single administration at the surgical site, with the goal of reducing the use of opioids for post-surgical pain. The study was conducted in a validated porcine post-operative pain model, using von Frey methodology, to assess both analgesic efficacy and PK properties of the two extended-release formulations. PRF-110 and Zynrelef demonstrated similar reductions in mechanical sensitivity, as measured by the von Frey test, indicating comparable pain-relief performance. PRF-110 exhibited a slower absorption rate relative to Zynrelef, suggesting a more gradual release of ropivacaine at the site of administration. PRF-110 showed increased retention in local tissue along with higher local tissue exposure, supporting prolonged availability of the active compound at the target site. Both formulations demonstrated sustained systemic and local drug levels, reinforcing their potential as long-acting analgesic solutions. PRF plans to continue advancing PRF-110 through additional studies to further validate its safety, efficacy and clinical utility across broader surgical settings.

PRF Technologies files to sell 7.5M ordinary shares for holders

PRF Technologies announced positive results from a preclinical study in domestic pigs directly comparing its lead product candidate, PRF-110, to Zynrelef, an approved extended-release product used as a benchmark in the study. Key Results: PRF-110 and Zynrelef each produced clear reductions in pain-related measures, confirming post-operative analgesic activity for both extended-release local analgesic formulations. Across the overall 72-hour assessment period, PRF-110's analgesic effect was comparable to Zynrelef on the primary efficacy endpoints evaluated in this head-to-head preclinical setting. At later post-operative timepoints, PRF-110 maintained analgesic efficacy comparable to ZYNRELEF, supporting the sustained-release characteristics of PRF-110 following a single administration. PRF-110's safety and local tolerability profile in pigs was consistent with prior preclinical experience, with no unexpected findings observed at the doses tested.